Investor Site Visit

RNS Number : 8550R
Advanced Medical Solutions Grp PLC
10 November 2011

10 November 2011


Advanced Medical Solutions Group plc 

(“AMS” or “the Company”)


Investor site visit


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, will today be hosting a site visit at Winsford for a number of institutional investors.


No new trading or financial information will be disclosed during the visit.


ends –


For further information, please visit or contact:


Advanced Medical Solutions Group plc

Chris Meredith, Chief Executive Officer                                                         Tel: +44 (0) 1606 545508

Mary Tavener, Finance Director


Tavistock Communications

John West / Chris Munden / Andrew Dunn                                                   Tel: +44 (0) 20 7920 3150


Investec Bank plc

Gary Clarence / Daniel Adams                                                                    Tel: +44 (0) 20 7597 5970


Notes to Editors:


About Advanced Medical Solutions Group plc – see


Founded in 1991, AMS is a leading company in the development and manufacture of innovative and technologically advanced products for the US$15 billion global wound care market. These products are sold in countries across the globe either directly or through a number of strategic partners and distributors.


AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids, provide an optimal environment for healing to occur and, in the case of silver alginates, include a safe and effective broad-spectrum anti-microbial agent for infection control.


AMS’ wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.


This information is provided by RNS
The company news service from the London Stock Exchange